Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs

被引：0
|
作者：
Mease, Philip [1 ]
Lertratanakul, Apinya [2 ]
Strober, Bruce [3 ,4 ]
Tsuji, Shigeyoshi [5 ]
Richette, Pascal [6 ]
Lovan, Charlie [2 ]
Feng, Dai [2 ]
Anderson, Jaclyn K. [2 ]
Van den Bosch, Filip [7 ]
机构：
[1] Seattle Rheumatol Associates PLLC, Seattle, WA USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Yale Univ, Sch Med, New Haven, CT USA
[4] Cent Connecticut Dermatol, New Haven, CT USA
[5] Natl Hosp Org, Osaka Minami Med Ctr, Dept Orthopaed Rheumatol, Osaka, Japan
[6] Lariboisiere Hosp, Dept Rheumatol, Paris, France
[7] Ghent Univ Hosp, Ghent, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
INADEQUATE RESPONSE; DOUBLE-BLIND; SAFETY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1356
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs
    Wells, Alvin E.
    Lee, Yvonne C.
    Tundia, Namita
    Suboticki, Jessica
    Chen, Kun
    Friedman, Alan
    Strand, Vibeke
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [22] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [23] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [24] Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
    Min, Hong Ki
    Kim, Se Hee
    Kim, Hae-Rim
    Lee, Sang-Heon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [25] STRATEGIES FOR THE USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PSORIATIC ARTHRITIS, INCLUDING TREAT TO TARGET
    Helliwell, Philip
    RHEUMATOLOGY, 2016, 55 : 22 - 22
  • [26] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [27] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [28] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin F.
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica L.
    Fleischmann, Roy
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 29 - 30
  • [29] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Shimada, Hiromi
    Kameda, Tomohiro
    Kanenishi, Kenji
    Miyatake, Nobuyuki
    Nakashima, Shusaku
    Wakiya, Risa
    Kato, Mikiya
    Miyagi, Taichi
    Mansour, Mai Mahmoud Fahmy
    Hata, Toshiyuki
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458
  • [30] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
    Tawaratsumida H.
    Setoguchi T.
    Arishima Y.
    Ohtsubo H.
    Akimoto M.
    Ishidou Y.
    Nagano S.
    Taketomi E.
    Sunahara N.
    Komiya S.
    BMC Research Notes, 10 (1)
12345